Original BioMedicals Co., Ltd.
Original BioMedicals Co., Ltd., engages in the development of new drugs with non-new ingredients in Taiwan. It develops OBM-A01, for the treatment of acute radiation injury, including nuclear radiation and solar radiation exposed in space; OBM-B01, a cyanide compound drug for protection against toxic gases from fires; and CCM-CL, a cyclic polypeptide antibiotic. The company was founded in 2011 an… Read more
Original BioMedicals Co., Ltd. (6483) - Net Assets
Latest net assets as of June 2025: NT$210.37 Million TWD
Based on the latest financial reports, Original BioMedicals Co., Ltd. (6483) has net assets worth NT$210.37 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$233.55 Million) and total liabilities (NT$23.19 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$210.37 Million |
| % of Total Assets | 90.07% |
| Annual Growth Rate | 33.35% |
| 5-Year Change | 572.32% |
| 10-Year Change | N/A |
| Growth Volatility | 164.61 |
Original BioMedicals Co., Ltd. - Net Assets Trend (2019–2024)
This chart illustrates how Original BioMedicals Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Original BioMedicals Co., Ltd. (2019–2024)
The table below shows the annual net assets of Original BioMedicals Co., Ltd. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$255.25 Million | -22.31% |
| 2023-12-31 | NT$328.57 Million | +374.98% |
| 2022-12-31 | NT$69.17 Million | -36.60% |
| 2021-12-31 | NT$109.11 Million | +187.38% |
| 2020-12-31 | NT$37.97 Million | -37.24% |
| 2019-12-31 | NT$60.49 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Original BioMedicals Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 24356200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$659.92 Million | 258.53% |
| Other Comprehensive Income | NT$4.33 Million | 1.70% |
| Other Components | NT$379.83 Million | 148.81% |
| Total Equity | NT$255.25 Million | 100.00% |
Original BioMedicals Co., Ltd. Competitors by Market Cap
The table below lists competitors of Original BioMedicals Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TMT Steel Public Company Limited
BK:TMT
|
$26.19 Million |
|
J8D0
F:J8D0
|
$26.20 Million |
|
Quonia SOCIMI SA
MC:YQUO
|
$26.22 Million |
|
Grand Baoxin Auto Group Limited
PINK:GBXXY
|
$26.22 Million |
|
MCH Group AG
SW:MCHN
|
$26.19 Million |
|
Q linea AB
ST:QLINEA
|
$26.19 Million |
|
Perfect Medical Industry Co., Ltd.
TWO:6543
|
$26.19 Million |
|
Rumble Resources Ltd
AU:RTR
|
$26.18 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Original BioMedicals Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 328,566,000 to 255,254,000, a change of -73,312,000 (-22.3%).
- Net loss of 74,998,000 reduced equity.
- New share issuances of 2,917,000 increased equity.
- Other comprehensive income increased equity by 190,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-75.00 Million | -29.38% |
| Share Issuances | NT$2.92 Million | +1.14% |
| Other Comprehensive Income | NT$190.00K | +0.07% |
| Other Changes | NT$-1.42 Million | -0.56% |
| Total Change | NT$- | -22.31% |
Book Value vs Market Value Analysis
This analysis compares Original BioMedicals Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.24x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 6.48x to 4.24x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$2.53 | NT$16.40 | x |
| 2020-12-31 | NT$1.37 | NT$16.40 | x |
| 2021-12-31 | NT$2.62 | NT$16.40 | x |
| 2022-12-31 | NT$1.48 | NT$16.40 | x |
| 2023-12-31 | NT$6.66 | NT$16.40 | x |
| 2024-12-31 | NT$3.87 | NT$16.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Original BioMedicals Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -29.38%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-29.38%) is above the historical average (-48.43%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -62.24% | 0.00% | 0.00x | 1.55x | NT$-43.70 Million |
| 2020 | -91.52% | 0.00% | 0.00x | 1.78x | NT$-38.54 Million |
| 2021 | -31.05% | 0.00% | 0.00x | 1.26x | NT$-44.79 Million |
| 2022 | -58.23% | -37642.06% | 0.00x | 1.42x | NT$-47.19 Million |
| 2023 | -18.16% | -138746.51% | 0.00x | 1.13x | NT$-92.52 Million |
| 2024 | -29.38% | 0.00% | 0.00x | 1.09x | NT$-100.52 Million |
Industry Comparison
This section compares Original BioMedicals Co., Ltd.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,528,453,600
- Average return on equity (ROE) among peers: 3.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Original BioMedicals Co., Ltd. (6483) | NT$210.37 Million | -62.24% | 0.11x | $26.19 Million |
| Grape King Bio Ltd (1707) | $11.79 Billion | 12.28% | 0.30x | $413.97 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $8.14 Billion | 10.26% | 0.37x | $160.24 Million |
| Maywufa Co Ltd (1731) | $2.11 Billion | 8.22% | 0.51x | $41.33 Million |
| Allied Biotech Corporation (1780) | $1.17 Billion | 8.33% | 0.78x | $47.92 Million |
| ScinoPharm Taiwan Ltd (1789) | $9.38 Billion | 5.16% | 0.21x | $180.77 Million |
| GeneFerm Biotechnology Co Ltd (1796) | $396.19 Million | 1.14% | 1.48x | $24.30 Million |
| Easywell Biomedicals Inc. (1799) | $696.90 Million | -39.00% | 0.68x | $62.14 Million |
| LIWANLI Innovation Co Ltd (3054) | $799.59 Million | 4.48% | 0.55x | $49.55 Million |
| YungShin Global Holding Corp (3705) | $4.70 Billion | 6.21% | 0.18x | $292.12 Million |
| TTY Biopharm Co Ltd (4105) | $6.11 Billion | 22.00% | 0.56x | $486.74 Million |